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Background: In ulcerative colitis (UC) 5-aminosalicylic acid (5-ASA)
is recommended as primary therapy for mild to moderate disease.
Topical 5-ASA has been proven especially eﬀective. In Crohn’s dis-
ease (CD) the evidence for a beneﬁcial role of 5-ASA is weak. We
investigated the use of topical and systemic 5-ASA therapy in children
and adolescents with inﬂammatory bowel disease.
Materials and Methods: Data of patients younger than 18 years,
registered between April 2008 and December 2015 in the Swiss
Inﬂammatory Bowel Disease Cohort, were analyzed.
Results: Three hundred twenty pediatric inﬂammatory bowel dis-
ease patients were included; 189 with CD and 131 with UC. Over
one third of UC patients [51 (39%)] received topical 5-ASA therapy
and 43 (33%) received combination therapy during their disease
course. UC patients with left-sided colitis or proctitis were more
likely to receive topical or combination therapy as compared with
patients with pancolitis (P<0.001 and <0.001, respectively). An
increase in the use of topical 5-ASA therapy in UC patients was
noted over time from 5% to 38%. Forty-seven percent of CD
patients were treated with oral 5-ASA during their disease course.
The usage was stable over time at approximately 15% to 20%.
Conclusions: In recent years a very positive trend showing an
increase in topical 5-ASA therapy in children and adolescents with
UC has been observed. However topical therapy is still used with
relative low frequency, especially in patients with a more extensive
disease. Conversely, despite weak evidence supporting 5-ASA use
in CD patients it has been frequently prescribed. Physicians should
continue to encourage their UC patients to use topical therapy.
Key Words: ulcerative colitis, Crohn’s disease, 5-ASA, topical
therapy, treatment
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Inﬂammatory bowel disease (IBD) is a chronic diseasewith recurrent episodes of active illness punctuated by
periods of remission. There are 2 major forms of IBD:
ulcerative colitis (UC) and Crohn’s disease (CD). The 2
subtypes diﬀer in symptomology and localization patterns.
This explains overlapping treatment strategies yet diﬀering
eﬃcacy of medications depending on the subtype.1,2
For mild to moderate UC 5-aminosalicylic acid
(5-ASA) is the primary treatment choice for induction and
maintenance of remission in pediatric and adult patients.2,3
Topical 5-ASA has been proven eﬀective especially in distal
disease in both children and adults.4 Several studies have
shown combination therapy of oral and topical 5-ASA to
be more eﬀective than monotherapy, even in extensive
disease.5,6 This is particularly important in pediatric
patients, who present with extensive disease more often
than adults.7
Topical steroid preparations have also been used to
treat UC, although they are slightly inferior to topical
5-ASA in inducing remission.8 They provide an alternative
treatment option for patients who are intolerant to
5-ASA.9 Importantly the combination of topical 5-ASA
and topical steroids seems to be superior to a single-agent
therapy.10
The value of 5-ASA in CD therapy is controversial.11
Despite the controversy and lack of evidence for ther-
apeutic beneﬁt many CD patients undergo 5-ASA treat-
ment during their disease course.12 The likelihood of having
used 5-ASA appears to be associated with longer disease
duration and colonic location at CD diagnosis.12 There are
no data available about topical 5-ASA therapy in colonic
CD.
On the basis of the currently available data, topical
therapy with its favorable risk-beneﬁt proﬁle of good eﬃ-
cacy and low rate of side eﬀects should be employed
whenever possible in UC patients. Unfortunately, data
from adult patients has demonstrated that the frequency of
topical therapy is relatively low, even in patients with
proctitis and left-sided colitis.13
The aim of this study was to investigate the use of
topical and systemic 5-ASA therapies in children and
adolescents with inﬂammatory bowel disease in the Swiss
IBD cohort. We hypothesized that in pediatric UC patients
topical therapy is used more often after the publishing of
new treatment guidelines.2 We also asked whether there is a
disease location dependency for 5-ASA use in UC patients
and examined the evolution of oral 5-ASA use in CD
patients over time.
MATERIALS AND METHODS
Since the end of 2006 the Swiss IBD Cohort Study
(SIBDCS) has been retrospectively and prospectively col-
lecting data on adult IBD patients in Switzerland.14 In
addition, data on pediatric patients have been collected by
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the SIBDCS since 2008. Patients are recruited by pediatric
gastroenterologists during regular follow-up. Owing to the
structure of the health care system in Switzerland nearly all
pediatric gastroenterologists are hospital-based and the
majority of pediatric IBD patients are followed in pediatric
academic health centers or specialized clinics. Inclusion
criteria are an established IBD diagnosis at least 4 months
before enrollment and a diagnosis based on Lennard-Jones
diagnostic criteria, conﬁrmed by radiology, endoscopy, or
surgery.15 The study is approved by local ethic committees,
and informed consent was obtained from patients and/or
their caregivers before inclusion in the SIBDCS.
Our data analysis included pediatric and adolescent
IBD patients under the age of 18. SIBDCS data regarding
diagnosis, age at diagnosis, gender, weight, height at diag-
nosis, initial disease location, and medication history were
retrieved. Patients with a change of diagnosis during
follow-up and IBD unclassiﬁed were excluded from
analysis.
Statistics
Data were analyzed with Stata (v14.1; StataCorp,
College Station, TX). Continuous data distribution was
assessed using normal QQ plots. Distribution of con-
tinuous Gaussian data was summarized as mean±SD
and range, whereas distribution of non-Gaussian data was
presented as median, interquartile range, and range. Dif-
ferences in Gaussian-distributed data means between
2 groups were assessed using the Student t test, and in non-
Gaussian data by using the Wilcoxon Mann-Whitney
rank-sum test.
Categorical data were summarized as frequency and
group percentages. The w2 test or the Fisher exact test in
cases with insuﬃcient sample size was used for diﬀerences
in categorical data distribution across groups, for paired
nominal data McNemar test was utilized. The Bonferroni
correction was applied in cases with multiple testing. Mul-
tilevel mixed-eﬀect logistic modeling was used to assess the
eﬀect of covariates on binary outcomes when dealing with
repeated measurements. A P-value <0.05 was considered
as statistically signiﬁcant.
RESULTS
Baseline Characteristics
In total, 354 pediatric and adolescent patients were
enrolled in the SIBDCS between April 2008 and December
2015. After excluding 11 patients as they changed diagnosis
during follow-up and 23 patients because they were diag-
nosed with IBD unclassiﬁed, 320 patients were included in
the analysis (Table 1). Gender distribution diﬀered in CD
with more males diagnosed, whereas in UC gender dis-
tribution was nearly equal. There was no diﬀerence in age
at diagnosis between CD and UC (P=0.091); however,
CD patients weighed signiﬁcantly less (P=0.015) and had
a lower body mass index (P=0.006).
A ﬁrst year follow-up was completed for 223 (69.7%)
patients, whereas the remaining 97 (30.3%) had only a
documented enrollment visit. Furthermore in 82 (25.6%)
patients 3 or more yearly follow-ups were available for
analysis.
Analyzing disease location at diagnosis revealed that
most UC patients presented with extensive colitis or pan-
colitis [88 (67%)] and only 24 (18%) with left-sided colitis
or proctitis [13 (10%)] (Table 2). Most CD patients had
ileocolonic disease, whereas a minority presented with ileal-
only or colonic-only disease [according to Paris classi-
ﬁcation: L1 (ileal) 24 (13%), L2 (colonic) 24 (13%), L3
(ileocolonic) 127 (67%), L4 (upper only) 3 (2%)]. Disease
location was not stated in 11 (6%) CD patients and 6 (5%)
UC patients.
Oral and Topical 5-ASA and Topical Steroids
Almost 40% of UC patients were ever treated with
topical 5-ASA. UC patients with left-sided colitis or proc-
titis were more likely to receive topical or combination
therapy as compared with patients with pancolitis
(P<0.001 and <0.001, respectively) (Table 2). Topical
steroid therapy was used to treat UC patients less fre-
quently than topical 5-ASA (15% vs. 39%, respectively,
P<0.001). A minority of patients received both topical 5-
ASA and topical steroids.
For CD, 13 patients were treated with topical 5-ASA; all
presented with colonic or ileocolonic disease at diagnosis.
TABLE 1. Baseline Characteristics of Study Population
Characteristics
All IBD Patients
(320)
CD Patients
[189 (59.1%)]
UC Patients
[131 (40.9%)] P, CD vs. UC
Gender
Male 174 (54.4) 109 (57.7) 65 (49.6) 0.155
Female 146 (45.6) 80 (42.3) 66 (50.4)
Age at diagnosis (y) (median, IQR) 12, 9-14 12, 10-14 12, 9-14 0.091
Age at enrollment (y) (median, IQR) 14, 12-16 14, 12-16 14, 12-16 0.243
BMI z score at enrollment (mean, SD) 0.28, 1.06 0.42, 1.09 0.08, 0.98 0.006
Height z score at enrollment (mean, SD) 0.28, 2.11 0.41, 1.94 0.09, 2.33 0.189
Weight z score at enrollment (mean, SD) 0.40, 1.17 0.57, 1.16 0.16, 1.17 0.015
Age at latest FUP (y) (median, IQR) 16, 14-17 17, 14-17 16, 13-17 0.141
Disease duration (y) (median, IQR)* 3, 2-5 3, 2-5 3, 1-6 0.757
Follow-up [n (%)]
Enrollment only 97 (30.3) 54 (28.6) 43 (32.8)
1st year FUP 83 (25.9) 47 (24.9) 36 (27.5)
2nd year FUP 58 (18.1) 39 (20.6) 19 (14.5)
3rd year FUP or more 82 (25.6) 49 (25.9) 33 (25.2) 0.515
*Disease duration=age at last follow-upage at diagnosis.
BMI indicates body mass index; CD, Crohn’s disease; FUP, follow-up; IBD, inﬂammatory bowel disease; IQR, interquartile range; UC, ulcerative colitis.
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Nearly 50% of CD patients received oral 5-ASA during their
disease course (Table 3).
Combination therapy of topical and oral 5-ASA was
given to 32.8% of UC patients and 3% of CD patients
(P<0.001).
The use of topical 5-ASA was found to be independent
of disease duration [median disease duration (interquartile
range, range) users versus nonusers, 3 y (1 to 6, 0 to 9) and
3 y (2 to 5, 0 to 16), respectively, P=0.558] and age of
diagnosis [11 y (9 to 13, 3 to 17) and 12 y (10 to 14, 0 to 17),
respectively, P=0.059]. Topical 5-ASA users were more
likely to be female than male, although this diﬀerence was
not statistically signiﬁcant [36 (56.3%) and 28 (43.7%),
respectively, P=0.059].
Analysis of the usage per year revealed an increase in
the use of topical 5-ASA therapy in UC patients over time
(from <5% in 2009 to >38% in 2015) (Fig. 1A). This
increase in percentage treated with topical 5-ASA was
statistically signiﬁcant in 2014 and 2015 with respect to
previous years (P=0.022). In addition, for the years 2013,
2014, and 2015, increases in the continuous use of topical 5-
ASA could be documented of 5.1%, 7.3%, and 12.8%,
respectively. In CD patients the usage of oral 5-ASA was
stable over time as each year 15% to 20% of CD patients
received oral 5-ASA (Fig. 1B).
Other Medications
There was no diﬀerence in the use of systemic steroid
therapy between UC and CD patients (P=0.527) (Table 3).
Budesonide was used to treat CD patients signiﬁcantly more
often than UC patients (P<0.001). Signiﬁcantly more CD
than UC patients received anti-tumor necrosis factor-a anti-
body therapy (P<0.001). CD patients were also treated more
often with immunomodulators and antibiotics than UC
patients (P<0.001 and 0.018, respectively).
DISCUSSION
In this study we described the treatment modalities of
children and adolescents with inﬂammatory bowel diseases
and focused on 5-ASA therapy.
As expected and in concordance with actual guide-
lines1,2 treatment strategies diﬀered between patients with
CD and UC. Patients with CD received systemic therapy
with budesonide, anti-tumor necrosis factor-a antibodies,
immunomodulators, and antibiotics signiﬁcantly more
often than UC patients. Oral and topical 5-ASA was used
signiﬁcantly more often as a treatment in UC patients.
5-ASA in UC
As previously described for other pediatric cohorts7
most of our pediatric and adolescent UC patients already
presented with extensive disease at diagnosis and only a
minority with proctitis. Topical 5-ASA was shown to be
eﬀective in children with proctitis4 and the majority of
patients in our cohort with proctitis received topical 5-ASA.
As combining oral 5-ASA with topical 5-ASA is more
eﬀective than oral alone, combination therapy should be
oﬀered for induction of remission for mild to moderate
disease even in extensive disease according to the actual
evidence-based treatment guideline.2 In our cohort only
38.9% of UC patients had ever been treated with topical 5-
ASA and 32.8% with combination therapy of oral and
topical 5-ASA. Despite these relatively low numbers, there
was a very gratifying trend in our cohort of increased
prescription of topical 5-ASA in the years subsequent to
publication of the new treatment guidelines in 2012.2 In
addition, more patients in our study were treated with
TABLE 2. 5-ASA and Steroid Therapy in UC Patients Depending on Disease Location
Medication
Pancolitis
[88 (70.4%)]
Left-sided
[24 (19.2%)]
Proctitis
[13 (10.4%)]
Overall
P
P, Pancolitis vs. Left-sided
Plus Proctitis
Oral 5-ASA 83 (94.3) 24 (100.0) 10 (76.9) 0.032 0.613
Topical 5-ASA 26 (29.5) 14 (58.3) 11 (84.6) <0.001 <0.001
Oral+ top 5-ASA 21 (23.9) 14 (58.3) 8 (61.5) 0.001 <0.001
Systemic steroids 69 (78.4) 16 (66.7) 6 (46.2) 0.038 0.030
Topical steroids 10 (11.4) 5 (20.8) 3 (23.1) 0.280 0.136
Six UC patients were excluded from analysis due to unknown disease location at diagnosis.
5-ASA indicates 5-aminosalicylic acid; UC, ulcerative colitis.
TABLE 3. Medication Use in General
Medication All IBD Patients (320) CD Patients [189 (59.1%)] UC Patients [131 (40.9%)] P, CD vs. UC
Oral 5-ASA 211 (65.9) 89 (47.1) 122 (93.1) <0.001
Topical 5-ASA 64 (20.0) 13 (6.9) 51 (38.9) <0.001
Oral+ top 5-ASA 49 (15.3) 6 (3.1) 43 (32.8) <0.001
Systemic steroids 238 (74.4) 143 (75.7) 95 (72.5) 0.527
Budesonide 46 (14.4) 40 (21.2) 6 (4.6) <0.001
Top steroids 33 (10.3) 14 (7.4) 19 (14.5) 0.040
Top 5-ASA+top steroids 13 (4.1) 4 (2.1) 9 (6.9) 0.044
Antibiotics 107 (33.4) 73 (38.6) 34 (26.0) 0.018
Immunomodulators 253 (79.1) 169 (89.4) 84 (64.1) <0.001
anti-TNF-a antibody 139 (43.4) 104 (55.0) 35 (26.7) <0.001
5-ASA indicates 5-aminosalicylic acid; CD, Crohn’s disease; IBD, inﬂammatory bowel disease; TNF-a, tumor necrosis factor-a; top, topical; UC, ulcerative
colitis.
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topical therapy as compared with a similar study in adults,
in which only 17.7% of a cohort of 773 UC patients had
ever received topical 5-ASA therapy and only 9.3% a 5-
ASA combination therapy.13
There are diverse explanations for the low frequency
of topical therapy usage. Physician’s reservations for pre-
scribing topical therapies due to assumed inconvenience for
the patients may be one factor. Another factor could be
diﬃculties in following a daily dosage regimen due to
school and sport commitments. A busy life style was one of
the most common reasons reported by adult patients for
intentional nonadherence to rectal therapy in an observa-
tional study.16 However, frequency may be tailored to
individual patient needs. In a randomized controlled trial
involving UC patients in remission weekend application of
5-ASA enema in combination with oral 5-ASA signiﬁcantly
reduced the incidence of relapses.17 This indicates that a
once-daily administration is not always required and a less
frequent schedule adjusted to the patients’ schedule may be
also eﬀective.
Studies examining health-related quality of life
actually showed an improvement in patients on combina-
tion therapy.6,18 This increase in quality of life was attrib-
uted to signiﬁcant diﬀerences in mobility, usual care, and
anxiety/depression. One contributing factor may be the
shorter time to bleeding cessation documented with the use
of topical therapy.5,6 Interestingly, when queried on future
usage, the majority of patients saw themselves prepared to
use combination therapy again in the future.6 Thus com-
bination therapy should be reoﬀered during the disease
course.
Diﬀerent 5-ASA formulations, including foam and
liquid enema, are available with comparable eﬃcacy.19
Foam retention was shown to be signiﬁcantly better than
liquid retention and may be the preferred formulation in
patients with a severely inﬂamed rectum.19 Topical therapy
and the diﬀerent formulations should be explained to
patients and explored whenever possible.
5-ASA in CD
Previously it was reported that 5-ASA is frequently
prescribed in adult CD patients12 despite lack of scientiﬁc
support for a beneﬁcial role.20 Furthermore nearly half of
the CD patients in our cohort were treated with oral 5-ASA
during their disease course. Earlier pediatric studies which
suggested a possible beneﬁt of 5-ASA in the treatment of
small intestinal CD21 may have inﬂuenced these prescribing
practices. Consequentially 5-ASA was considered a val-
uable treatment option in mild to moderate pediatric CD in
previous consensus summaries.22 However a recent meta-
analysis has reaﬃrmed that 5-ASA has little beneﬁt for the
treatment of active CD.20 In concordance with this evidence
the actual treatment guideline for pediatric CD recom-
mends oral 5-ASA only for selected patients with a very
mild colonic disease.1 Only 13% of CD patients in our
cohort had colonic-only disease at diagnosis, whereas
nearly half of all CD patients received oral 5-ASA at some
time point. The yearly prescription rate of 5-ASA in CD
patients was stable between 2009 and 2015; however, the
eﬀect and the adjustment of treatment modalities from the
2014 published pediatric guideline may not yet be evident.
A recent study from Israel comparing the intent to use
speciﬁc treatments in adult and pediatric IBD patients
showed that 60% of pediatric gastroenterologists would use
5-ASA in mild CD and 21% in Crohn’s colitis,23 indicating
that 5-ASA use in pediatric CD is still common and not
speciﬁc for Switzerland.
Interestingly, 1 study in adults demonstrated that
physicians perceived a clinical response to 5-ASA in nearly
half of their CD patients.12 Whether this represents a true
drug eﬀect or simply a biased patient selection with a priori
benign natural course of CD is debatable, as it is known
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FIGURE 1. Change of 5-aminosalicylic acid (5-ASA) use over time. A, Analysis of the 5-ASA usage per year from 2009 to 2015 revealed a
gradual increase in the use of topical 5-ASA therapy in ulcerative colitis (UC) patients. B, Oral 5-ASA use in Crohn’s disease (CD) patients
was stable over the same time period. The number in parentheses indicates the number of patients diagnosed in the given year. First
time treated, inclusion of 5-ASA into therapy; continuously treated, 2 or more consecutive years of 5-ASA treatment including the given
year.
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that Crohn’s colitis can remain uncomplicated for many
years in the adult population.24 In pediatric CD the disease
course in general is less benign. However, whether there
exists a similar perception among pediatric gastro-
enterologists and the extent to which the adult perception
inﬂuences the pediatric one remains speculative.
Another pertinent factor for 5-ASA prescription in
CD especially in pediatrics may be that 5-ASA is regarded
as a mild and safe medication with a low side eﬀect rate,
reducing the threshold for prescription. However, there is a
potential for severe side eﬀects25 and therefore all pre-
scriptions should be carefully evaluated to appropriately
weigh risk and beneﬁts.
Strength and Limitations
A major strength of this study is the size of the cohort
with coverage of the majority of pediatric and adolescents
IBD patients in Switzerland. These patients are almost uni-
versally cared for at pediatric academic health centers or
specialized clinics in Switzerland which are part of the
SIBDCS. Another strength is the covered time period of 7
years with a systematic recording of patients’ data. This
allowed us to determine some trends in treatment modalities.
The main limitation of our study is the retrospective obser-
vational design in which database records are analyzed. This
design does not enable assessment of adherence to the pre-
scribed medication or clinical response. However, the docu-
mented increase in the number of continuously topical 5-ASA
treated patients may indicate good compliance.
CONCLUSIONS
Topical therapy is still underused in children and ado-
lescent with UC, although a very positive trend of increased
prescription and continuously use could be noted. Physicians
should continue to encourage and educate their patients to
improve adherence to and compliance with a therapy which
may initially appear very unpleasant. Optimized utilization of
diﬀerent frequency regimens and drug formulations may
further promote compliance and adherence.
In contrast oral 5-ASA is still used frequently in
pediatric and adolescent CD patients despite a lack of
strong supporting evidence. This gap between scientiﬁc
evidence and clinical practice may close with the further
spread of guidelines.
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